

CNBS

AMPLIFY SEYMOUR
CANNABIS ETF

As of 3/31/22

Actively Managed by Cannabis
Investment Professional Tim Seymour



THE CNBS DIFFERENCE


- **Purity** – 80% of the portfolio companies with 50% or more of their revenue from the cannabis and hemp ecosystem. CNBS is comprised of stocks with no derivative exposure.
- **Portfolio Manager** - CNBS is an actively managed portfolio which allows the ETF to adjust its holdings on a daily basis. Tim Seymour is the portfolio manager of CNBS. Tim has over 20 years of general investment experience and has been an early stage investor and recognized voice in the cannabis industry. He serves as a board member or in an advisory role for several private cannabis companies and provides regular commentary as a host on CNBC's show Fast Money.
- **Legal Review** - CNBS will only hold companies deemed to be abiding by the federal laws within the countries they operate.
- **Diversification** - CNBS will hold a basket of companies diversified by industry, market cap and business focus, which helps to mitigate single stock risk.

WHY INVEST IN CANNABIS-RELATED COMPANIES

1. **Consumer Demand** - By 2025, spending on legal cannabis is expected to double from 2021 – growing from \$16.5 billion over \$33 billion worldwide.¹
2. **Legalization** - Currently legal in some form in 47 US states and 21 countries, with more anticipated to come.
3. **Medical Use** - Over 100 naturally occurring compounds – cannabinoids – are found in the cannabis plant. Currently three FDA approved drugs exist that incorporate cannabis compounds; however, research into other use and application cases is dramatically increasing.

PORTFOLIO SELECTION

CNBS invests at least 80% of its assets in securities of companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem, across one of three classifications:



CNBS is an ETF investing in the fast-developing global cannabis industry. The Fund is managed by Tim Seymour, a recognized voice and experienced investor in the cannabis space.

FUND FACTS

| | |
|---------------------|-----------|
| Ticker | CNBS |
| CUSIP | 032108854 |
| Intraday NAV | CNBSIV |
| Inception Date | 7/23/2019 |
| Exchange | NYSE Arca |
| Actively Managed | |
| Number of Holdings* | 36 |

FEES & EXPENSES

| | |
|---------------------------------|---------|
| Management Fee | 0.65% |
| Other Expenses | 0.31% |
| | 0.96% |
| Less Fee Waiver/Reimbursement** | (0.21%) |
| Net Expense Ratio | 0.75% |

MARKET CAPITALIZATION

As Of 3/31/22

| | |
|----------------------------|--------|
| Large Cap (> \$10B) | 0.02% |
| Mid Cap (\$2B - \$10B) | 50.77% |
| Small Cap (< \$2B) | 36.50% |
| Micro Cap (<\$300 Million) | 12.71% |

COUNTRY ALLOCATION

As Of 3/31/22


| | |
|---------------|--------|
| United States | 64.00% |
| Canada | 33.29% |
| Ireland | 2.45% |
| Israel | 0.26% |

*as of 3/31/22

Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

CANNABIS SEGMENTS

As Of 3/31/22



* MSOs (Multi-State Operators) via total return SWAPs.

Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

TOP 10 HOLDINGS

As Of 3/31/22

| Ticker | Company | % Wt. |
|----------|-----------------------------|-------|
| GTBIF US | Green Thumb Industries Inc | 9.02% |
| MAPS US | WM Technology Inc | 8.51% |
| CURLF US | CuraLeaf Holdings Inc | 7.89% |
| TLRY US | Tilray Brands Inc | 7.87% |
| TCNNF US | Trulieve Cannabis Corp | 6.13% |
| CRLBF US | Cresco Labs Inc-Subordinate | 5.74% |
| CGC US | Canopy Growth Corp | 4.39% |
| VFF US | Village Farms International | 4.38% |
| VRNO CN | Verano Holdings Corp | 4.28% |
| AFCG US | AFC Gamma Inc | 4.18% |

CNBS PERFORMANCE

Quarter End as of March 31, 2022

| | Cumulative (%) | | | | | Annualized (%) | |
|---------------|----------------|---------|---------|---------|-----------------|----------------|-----------------|
| | 1 Mo. | 3 Mo. | 6 Mo. | YTD | Since Inception | 1 Yr. | Since Inception |
| Fund NAV | 2.63% | -11.56% | -35.22% | -11.56% | -48.63% | -56.65% | -21.91% |
| Closing Price | 2.20% | -11.25% | -34.96% | -11.25% | -48.66% | -56.83% | -21.93% |

Fund inception date: (7/23/2019). The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Brokerage commissions will reduce returns. For performance data current to the most recent month-end please call 855-267-3837 or visit AmplifyETFs.com/CNBS. Market price returns reflect the midpoint of the bid/ask spread as of the close of trading on the exchange where Fund shares are listed.

¹ Statista.com, Global legal adult-use cannabis market size from 2020 to 2025, Jan. 2022

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in Amplify Funds statutory and summary prospectus, which may be obtained above or by calling 855-267-3837, or by visiting AmplifyETFs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

The Fund is subject to management risk because it is an actively managed. Companies involved in the cannabis industry face competition, may have limited access to the services of banks, may have substantial burdens on company resources due to litigation, complaints or enforcement actions, and are heavily dependent on receiving necessary permits and authorizations to engage in medical cannabis research or to otherwise cultivate, possess or distribute cannabis. The possession and use of cannabis, even for

medical purposes, is illegal under federal and certain states' laws, which may negatively impact the value of the Fund's investments. Securities issued by non-U.S. companies present risks beyond those of securities of U.S. issuers.

Many of the companies in which the Fund will invest are engaged in other lines of business unrelated to cannabis and these lines of business could adversely affect their operating results. Cannabis is a Schedule I controlled substance under the Controlled Substances Act ("CSA"), meaning that it has a high potential for abuse, has no currently "accepted medical use" in the U.S., lacks accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may be less liquid and may experience greater price volatility than larger, more established companies as a result of several factors, including limited trading volumes, products or financial resources, management inexperience and less publicly available information. The Fund is non-diversified, which can cause greater share price fluctuation.

Amplify Investments LLC is the Investment Adviser to the Fund, and Penserra Capital Management, LLC

serves as the Investment Sub-Adviser.

Amplify ETFs are distributed by Foreside Fund Services, LLC.

** The Fund's investment adviser has contractually agreed to waive its advisory fees and/or assume as its own expense certain expenses otherwise payable by the Fund to the extent necessary to ensure that total annual fund operating expenses do not exceed 0.75% of average daily net assets until March 1, 2022.



QUESTIONS?

Visit AmplifyETFs.com/CNBS

Phone 855-267-3837

Email info@AmplifyETFs.com